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7Hepatocellular Carcinoma Screening With Computed
Tomography Using the Arterial Enhancement Fraction With
Radiologic-Pathologic Correlation
Adrian Thomas Huber, MD,*† Frederik Schuster, MD,* Lukas Ebner, MD,*‡ Yanik Bütikofer, MD,*
Daniel Ott, MD,* Lars Leidolt, MD,* Andreas Jöres, MD,* Matteo Montani, MD,§
Johannes Heverhagen, MD,* and Andreas Christe, MD*Objective: The aim of this study was to investigate the performance of the arte-
rial enhancement fraction (AEF) in multiphasic computed tomography (CT) acqui-
sitions to detect hepatocellular carcinoma (HCC) in liver transplant recipients
in correlation with the pathologic analysis of the corresponding liver explants.
Materials andMethods: Fifty-five transplant recipientswere analyzed: 35 patients
with 108 histologically proven HCC lesions and 20 patients with end-stage liver
disease without HCC. Six radiologists looked at the triphasic CT acquisitions
with the AEF maps in a first readout. For the second readout without the AEF
maps, 3 radiologists analyzed triphasic CT acquisitions (group 1), whereas the
other 3 readers had 4 contrast acquisitions available (group 2). A jackknife
free-response reader receiver operating characteristic analysis was used to
compare the readout performance of the readers. Receiver operating characteris-
tic analysis was used to determine the optimal cutoff value of the AEF.
Results: The figure of merit (θ = 0.6935) for the conventional triphasic readout
was significantly inferior compared with the triphasic readout with additional
use of the AEF (θ = 0.7478, P < 0.0001) in group 1. There was no significant
difference between the fourphasic conventional readout (θ = 0.7569) and the
triphasic readout (θ = 0.7615, P = 0.7541) with the AEF in group 2. Without
the AEF, HCC lesions were detected with a sensitivity of 30.7% (95% confi-
dence interval [CI], 25.5%–36.4%) and a specificity of 97.1% (96.0%–98.0%)
by group 1 looking at 3 CT acquisition phases and with a sensitivity of 42.1%
(36.2%–48.1%) and a specificity of 97.5% (96.4%–98.3%) in group 2 looking
at 4 CT acquisition phases. Using the AEF maps, both groups looking at the
same 3 acquisition phases, the sensitivity was 47.7% (95% CI, 41.9%–53.5%)
with a specificity of 97.4% (96.4%–98.3%) in group 1 and 49.8% (95% CI,
43.9%–55.8%)/97.6% (96.6%–98.4%) in group 2. The optimal cutoff for the
AEF was 50%.
Conclusion: The AEF is a helpful tool to screen for HCC with CT. The use of
the AEF maps may significantly improve HCC detection, which allows omitting
the fourth CT acquisition phase and thus making a 25% reduction of radiation
dose possible.
Key Words: computed tomography, liver CT perfusion,
hepatic nodule detection rate, HCC screening, radiation dose reduction,
orthotopic liver transplantation
(Invest Radiol 2016;51: 25–32)
H epatocellular carcinoma (HCC) is the fifth most frequent cancerand the second cause of cancer deaths worldwide.1 If an HCC is
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Copyright © 2015 Wolters Kluwer Hdetected early, patients can be cured in up to 90% of the cases under
the best circumstances.2 If not, survival rate lies between several years
for patients undergoing liver transplantation and several months for
patients without treatment options.3 The most cost-effective strategy
to screen patients with chronic liver disease for HCC is sonographywith
testing of the serum alpha-fetoprotein level every 6 months.4 But a low
sensitivity of ultrasound for HCC detection favors screening with com-
puted tomography (CT), especially for patients on the orthotopic liver
transplantation (OLT) list.5,6
During the last few years, there were several published papers
showing an increased detectability of HCC lesions with CT perfusion.7–10
Beneath the motion artefacts, 1 major limitation for CT perfusion is the
high radiation dose, especially in a setting of long-duration HCC sur-
veillance in patients on the OLT list.11 The calculation of the arterial
enhancement fraction (AEF), as introduced by Kim et al,12 allows the
calculation of a quantitative colored liver map using the raw data of a
standard CT scan with triphasic acquisition (unenhanced, arterial,
and portal venous phase). The AEF is calculated as the proportion
of the arterial to the portal venous attenuation, normalized by the under-
lying unenhanced liver attenuation: AEF = [(HUA − HUU)/(HUP −
HUU)]  100, where HU is the attenuation, A is the arterial phase,
P is the portal phase, and U is the unenhanced CT acquisition. An
HCC lesion that has a predominantly arterial blood supply is expected
to show a high AEF, in contrast to normal liver tissue with around
20% arterial blood and 80% portal venous blood supply.13
Kim et al showed a very high sensitivity of 88.8% for HCC
detection using the AEF maps. But they included only HCC lesions
detected on imaging studies, proven positive by surgery, biopsy, or
the recommendations from the American Association for the Study of
Liver Disease (AASLD) criteria.14 The rest of the liver parenchyma,
potentially containing other lesions that were not visible or not detected
on imaging studies, was considered normal without histologic correla-
tion. Also, patients with prior transarterial chemoembolization (TACE)
were excluded. This is a major weakness of their study because radiol-
ogists regularly see CT scans of patients with advanced disease on the
OLTwaiting list that have undergone previous TACE.
The aim of this study was to investigate the AEF in a realistic
HCC-surveillance setting in patients with advanced liver cirrhosis
on the OLTwaiting list. These results should be compared with the his-
tologic analysis of the whole liver explants serving as the gold standard.
Because the AEF tool uses a triphasic image acquisition, another as-
sumption would be if the use of the AEF tool would supersede the ac-
quisition of 4 contrast phases (unenhanced, arterial, portal venous, and
equilibrium phase) and thus allow a 25% reduction in radiation dose.
Furthermore, a comparison of the screening performance of the AEF
tool in liver segments with and without previous TACE was intended.
MATERIALS AND METHODS
This retrospective study received approval from the local ethics
committee. Transplantation candidates were selected by the MELD
and Milan criteria.15,16 All patients who underwent liver transplanta-
tion between 2010 and 2014 at a tertiary care institution werewww.investigativeradiology.com 25
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Huber et al Investigative Radiology • Volume 51, Number 1, January 2016reviewed. Included were patients with liver cirrhosis and pathologically
proven HCC as well as patients with liver cirrhosis but no HCC,
which was also pathologically proven. Excluded patients were those
with no cirrhosis, no availablemultiphaseCTof the liver in the 4months
before the liver transplantation, or patients with hepatic interventions
between the last liver CT and the transplantation, including surgery,
endovascular, and transcutaneous interventions to the liver. The result
was a total of 55 patients: 35 patients with liver cirrhosis and a total
of 108 pathologically proven HCC lesions, as well as 20 patients with
liver cirrhosis where pathological analysis of the explant excluded
any HCC lesion. Of the 108 HCC lesions, 47 lesions were already
treated by previous TACE, whereas 61 lesions remained without treat-
ment at the time of the liver transplantation. Twenty-seven HCC lesions
were larger than 2 cm, whereas 81 lesions measured 2 cm or less in long
axis diameter. Seventeen HCC lesions larger than 2 cm were treated
with TACE before the CTacquisitions, whereas 10 of the lesions larger
than 2 cm were not treated with TACE before the CT acquisition and
the liver transplantation. All inclusion and exclusion criteria as well
as the resulting HCC lesions are summarized in Figure 1.
Mapping of HCC Lesions
After liver transplantation, all the liver explants were syste-
matically analyzed by a hepatopathologist. First, he analyzed the gross
specimen macroscopically by cutting it into 1-cm-thick slices. Every
macroscopically suspect nodule was histologically analyzed and cate-
gorized as HCC or no HCC. Well-differentiated HCCs were termed
HCC lesions, whereas regenerative and dysplastic nodules were termed
no HCC. In a second step, all the HCC lesions defined by histopatho-
logic analysis were matched with the CT scans and localized on a seg-
mented liver scheme, considered as the true-positive HCC lesions; this
was done by 2 radiologists with 5 and 15 years' experience in abdo-
minal radiology. Imaging characteristics of the lesions on the CTacqui-
sitions were not taken into account. Nodules with some imaging
characteristics of HCC but declared negative by the hepatopathologist
were considered as no HCC. These were mainly nodules presenting
arterial enhancement without washout, mostly consistent with regener-
ative or dysplastic nodules.FIGURE 1. Inclusion and exclusion criteria of the patient population with the
26 www.investigativeradiology.com
Copyright © 2015 Wolters Kluwer HImage Acquisition
All the CT scanswere acquired in 4 contrast phases: unenhanced
before intravenous contrast administration, in the arterial phase at
35 seconds after intravenous contrast administration, in the portal ve-
nous phase at 70 seconds, and in the equilibrium phase at 3 minutes.
All the CTacquisitions were performed on a Siemens SomatomDefini-
tion Flash, a Siemens Somatom Definition Edge (Siemens Healthcare,
Erlangen, Germany), or a Philips CT Brilliance 64 CT scanner (Philips
Medical Systems, Best, the Netherlands). Tube voltage was set at
120 kVp with automated tube current modulation. Axial slices 1 and
5 mm thick were reconstructed. The AEF was calculated using the
1-mm unenhanced, arterial, and portal venous CT acquisitions, using
the AEF tool contained in the CToncology mode on a syngo.via work-
station by Siemens Healthcare (Erlangen, Germany).
Image Analysis
Six radiologists with 3 to 8 years' experience in abdominal radi-
ology, who did not have clinical information other than known liver cir-
rhosis, analyzed the CT images in 2 readout rounds. The 2 radiologists
who matched the histopathological results with the CT images did not
participate in this readout. The first readout was done with the AEF per-
fusion maps available and the second readout without AEF maps. The
second readout was performed at least 4 weeks after the first readout.
The readout round with the AEF tool was performed before the readout
round without the AEF tool to ensure that an eventually occurring rec-
ognition bias did not favor the AEF tool. For the first readout, the readers
looked at the triphasic grayscale images in conjunction with the color
AEF maps. The fourth acquisition phase (equilibrium phase) was not
available to any of the readers during the first readout round. The AEF
maps were shown in axial slices alone, as well as an overlay of the
AEF maps with the unenhanced grayscale CT images (30% AEF map
and 70% grayscale map) in axial, coronal, and sagittal reconstructions.
The polygonal region of interest (ROI) was set as large as possible in
the lesion on the AEF perfusion map, excluding eventual zones of ne-
crosis and major vessels. The readers were instructed not to measure
ROIs smaller than 5 mm whenever possible. A 1  1 cm reference
ROI was set in the normal parenchyma of each liver without containingresulting HCC lesions.
© 2015 Wolters Kluwer Health, Inc. All rights reserved.
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Investigative Radiology • Volume 51, Number 1, January 2016 Hepatocellular Carcinoma Screening With CTmajor vessels or liver lesions to record background liver tissue enhance-
ment characteristics. The readers noted the AEF values (in percentage)
on an Excel spreadsheet and allocated the lesions on the segmented liver
scheme. Each lesion was assigned a confidence number between 1 and
5 (1, minimal linear or point-shaped arterial enhancement, no washout;
2, weak, laminar arterial enhancement, no washout; 3, arterial enhance-
ment, uncertain washout or no arterial enhancement and clear washout;
4, weak arterial enhancement, clear washout; 5, strong arterial enhance-
ment, clear washout). The AEF perfusionmaps andmeasurementswere
used to either downgrade or upgrade the confidence of the conventional
grayscale images. Confidence 1 to 2 was considered as “no HCC
lesion” and confidence 3 to 5 was considered as “HCC lesion.”
For the second readout round without the AEF perfu
sion maps, the readers were separated into 2 groups with 3 readers each.
To compare triphasic with fourphasic acquisitions, the first group re-
ceived 3 CT acquisitions to evaluate (unenhanced, arterial, and portal
venous phase), whereas the second group had 4 CT acquisitions avail-
able (unenhanced, arterial, portal venous, and equilibrium phase).
Statistics
A receiver operating characteristic (ROC) analysis was used to
calculate the optimized cutoff values for the measured AEF values using
the MedCalc software, version 7.6.0.0. (Mariakerke, Belgium).17 The
ROC analysis was performed on a per-segment basis using the mea-
sured AEF values on the AEFmap in suspected HCC lesions. The con-
trol ROIs measured in normal hepatic tissue in each AEF map were
assigned to the segments considered as normal by the readers. Each
segment was considered either as true-positive or true-negative for
HCC as defined by the hepatopathologist as the gold standard.
A jackknife free-response reader ROC (JAFROC) analysis
using the confidence levels given by the readers for each identifiedFIGURE 2. Typical HCC with central tumor necrosis (A, B, C; white asterisk), w
(F; black arrow). The anterior and medial tumor borders show nodular arteria
arrows). On the lateral tumor border, arterial enhancement is not clearly seen
on the arterial enhancement (AEF) map (D; white arrow). On the correspondi
hypervascularity (F; black asterisk), and normal hepatocytes can be seen (E; bl
portal venous phase; D, arterial enhancement fraction (AEF) map; E and F, corre
© 2015 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2015 Wolters Kluwer Hlesion (1-5) was done to compare the 2 readouts. The analysis was per-
formed with a JAFROC analysis software, version 4.2.1 (available at
http://www.devchakraborty.com).18 The 2 groups of readers were ana-
lyzed separately: the triphasic readout with AEF compared with the
triphasic conventional readout without AEF for group 1 and the tripha-
sic readout with AEF compared with the fourphasic readout without
AEF for group 2. To compare 3 versus 4 phases' detectability, a paired
JAFROC analysis was performed. Because the true-positive lesions
have to be identical for JAFROC analysis, a comparison of segments
with previous TACE and segments without previous TACE was not
possible with this method. Instead, sensitivity, specificity and positive
predictive value (PPV) were calculated on a per-segment basis with a
contingency 2  2 table analysis.
To compare the serum alpha-fetoprotein levels with the mea-
sured AEF values and the pathologic tumor mass, a Spearman rank cor-
relation coefficient was calculated. The following variables have been
compared: the serum alpha-fetoprotein level of each patient, the sum
of the diameters of lesions with a mean AEF of 50% and more, in cen-
timeters, and the sum of the HCC diameters as measured by the pathol-
ogist in each patient.
For interreader variability, a nonweighted binary κ-statistic for
multiple readers was calculated (κ value 0–0.2, poor; 0.21–0.4, fair;
0.41–0.6, moderate; 0.61-0.8, substantial; 0.81–1, almost perfect),19,20
using the MedCalc software.17RESULTS
Optimal Cutoff and Performance of the AEF
Based on the present patient population, the optimal cutoff
AEF value was 50% to discriminate HCC from non-HCC lesions with
a sensitivity of 94.6% (95% confidence interval [CI] 91.3%–97.0%)hich can also be seen on the corresponding histopathologic image
l enhancement with washout in the portal venous phase (B, C; black
on the grayscale images (B, C; white arrows) but is easily detectable
ng histopathologic images, vital HCC cells (E, F; white arrows),
ack arrow). A, unenhanced scan; B, arterial phase; C,
sponding hematoxylin and eosin–stained histopathologic images.
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FIGURE 3. Well-differentiated HCC that is difficult to detect on the grayscale images with slight enhancement in the arterial phase and a minimal
washout in the portal venous phase (A, B, C; black arrows). The arterial enhancement (AEF) map allows detection of the hypervascular lesion (D; white
arrow). On the corresponding hematoxylin and eosin–stained histopathologic images, well-differentiated HCC cells (E) with acinar (black asterisk) and
trabecular growth pattern (white asterisk) are seen. A, unenhanced scan; B, arterial phase; C, portal venous phase; D, arterial enhancement fraction
(AEF) map; E, corresponding hematoxylin and eosin–stained histopathologic images.
Huber et al Investigative Radiology • Volume 51, Number 1, January 2016and a specificity of 92.8% (95% CI, 91.6%–94.0%). The area under
the curve was 0.957. Figures 2 and 3 show examples of HCC lesions
with the corresponding AEF map and histopathologic images.
The JAFROC analysis showed a significant difference in the figures
of merit (θ) between the triphasic conventional readout (θ = 0.6935) and
the triphasic readout with additional availability of the AEF (θ = 0.7478)
in group 1, with a P value of 0.0002. For group 2, there was a slightly,
but not significantly, higher figure of merit of the triphasic readout
with additional availability of the AEF (θ = 0.7615) compared with
the fourphasic conventional readout (θ = 0.7569), with a P value of
0.7541. A comparison of the AEF readout between the 2 groups of
readers, which consisted of identical analysis of triphasic conventio-
nal images with additional AEF maps, was minimal (P = 0.3482),
showing similar readout performance of the 2 groups of readers. The
conventional triphasic readout of group 1 (θ = 0.6935) was significantly
inferior to the conventional fourphasic conventional readout of groupTABLE 1. Results of the JAFROC Analysis
Without AEF With AEF P-value
Group 1 θ = 0.69 θ = 0.75 <0.01
Group 2 θ = 0.76 θ = 0.76 0.75
P < 0.01 0.35
Group 1 looked at 3 contrast acquisitions (unenhanced, arterial, and portal
venous) during the conventional readout, whereas group 2 had 4 contrast
acquisitions (unenhanced, arterial, portal venous, and equilibrium phase)
available. θ = figure of merit.
AEF indicates arterial enhancement fraction.
28 www.investigativeradiology.com
Copyright © 2015 Wolters Kluwer H2 (θ = 0.7569), with a P value of < 0.0001. The results of the JAFROC
analysis are shown in Table 1.
In the group looking at triphasic CT scans, HCC was detected
with a sensitivity of 30.7% (95% CI, 25.5%–36.4%) and a PPV of
72.0% (95% CI, 63.3%–79.7%) without the AEF, compared with a
sensitivity of 47.7% (95% CI, 41.9%–53.5%) and a PPV of 82.2%
(95% CI, 75.7%–87.6%) including the AEF. In the group looking
at fourphasic CT acquisitions, HCC lesions were detected with a sensi-
tivity of 42.1% (95% CI, 36.2%–48.1%) and a PPVof 80.1% (95% CI,
72.7%–86.3%) without the AEF, compared with a sensitivity of 49.8%
(95% CI, 43.9%–55.8%) and a PPVof 84.0% (95% CI, 77.6%–89.2%)
with the AEF (Table 2).
Interreader Variability
The κ statistic showed a moderate mean unweighted interreader
variability value of 0.42 without the AEF map (κ = 0.37/fair for the
triphasic readout and κ = 0.48/moderate for the fourphasic readout),
compared with a substantial mean unweighted interreader variability
value of κ = 0.62 for the readout with the AEF map including all
6 readers.
Correlation of the Measured AEF Values With Serum
Alpha-Fetoprotein Levels
There was a very good correlation of the sum of the lesion diam-
eters with AEF values greater than 50% with the sum of the lesion
diameters measured by the hepatopathologist (r = 0.85, P < 0.01)
(Table 3). On the other hand, there was a rather poor correlation be-
tween the measured serum alpha-fetoprotein levels and the AEF values
(r = 0.37, P = 0.01), as well as with the total HCC diameter measured
by the hepatopathogist (r = 0.33, P = 0.03).© 2015 Wolters Kluwer Health, Inc. All rights reserved.
ealth, Inc. All rights reserved.
TABLE 2. Comparison of the Sensitivity, the Specificity and the Positive Predictive Value (Precision) of the Different Readouts
Group 1 Group 2
Triphasic CTAcquisition Triphasic CTAcquisition Triphasic CTAcquisition Fourphasic CTAcquisition
With AEF Without AEF With AEF Without AEF
Sensitivity 47.7% (41.9%–53.5%) 30.7% (25.5%–36.4%) 49.8% (43.9%–55.8%) 42.1% (36.2%–48.1%)
Specificity 97.4% (96.4%–98.3%) 97.1% (96.0%–98.0%) 97.6% (96.6%–98.4%) 97.5% (96.4%–98.3%)
Positive predictive value 82.2% (75.7%–87.6%) 72.0% (63.3%–79.7%) 84.0% (77.6%–89.2%) 80.1% (72.7%–86.3%)
Interreader variability κ 0.59 0.37 0.63 0.48
The mean interreader variability κ between the readers in each group is shown on the last line for the 2 readouts (κ value 0–0.2, poor; 0.21–0.4, fair; 0.41–0.6, mod-
erate; 0.61–0.8, substantial; 0.81–1, almost perfect). For the first readout, every reader in both groups looked at the same AEF maps in adjunct to the triphasic CT ac-
quisitions (unenhanced, arterial, and portal venous phase). For the second readout, the AEF maps were not shown to the readers. The readers in group 1 looked at
triphasic CT acquisitions, whereas group 2 had 4 contrast acquisitions available (unenhanced, arterial, portal venous, and equilibrium phase). The 95% confidence in-
terval is indicated in parenthesis.
AEF indicates arterial enhancement fraction; TACE,transarterial chemoembolization.
TABLE 3. Correlation Between the Measured Serum Alpha-Fetoprotein Levels, AEF Values, and the Sum of the Lesion Diameters as Measured
by the Hepatopathologist
Sum of the Diameters of the Lesions
With an AEF >50%
Sum of the Lesion Diameters as
Measured by the Hepatopathologist
Serum alpha-fetoprotein levels r = 0.37 (P = 0.01) r = 0.33 (P = 0.03)
Sum of the lesion diameters as
measured by the hepatopathologist
r = 0.85 (P < 0.01)
AEF indicates arterial enhancement fraction.
Investigative Radiology • Volume 51, Number 1, January 2016 Hepatocellular Carcinoma Screening With CTDetection of HCC in Segments With and Without
Previous Tace
In liver segments with previous TACE treatment, HCC lesions
were detected with a sensitivity of 31.9% (95% CI, 26.8%–37.3%)
and a PPV of 85.1% (95% CI, 77.5%–90.9%) without the use of the
AEF map and with a sensitivity of 48.4% (95% CI, 42.9%–53.9%)
and a PPV of 91.5% (95% CI, 86.4%–95.2%) with the AEF perfusion
maps. Lesions in liver segments without previous TACE treatment, on
the other hand, have been detected with a sensitivity of 42.3% (95%
CI, 36.1%–48.8%) and a PPVof 69.5% (95%CI, 61.5%–76.8%)without
the use of the AEFmap andwith a sensitivity of 51.6% (95%CI, 45.2%–
57.9%) and a PPVof 75.0% (95% CI, 67.8%–81.3%) with the AEF map
(Table 4). Figure 4 shows an example of a recurrent HCC after previous
TACE with the corresponding AEF map and histopathologic images.
DISCUSSION
The use of the AEF significantly improved the sensitiv-
ity and the precision (PPV) of radiologists in HCC detection in aTABLE 4. Comparison of the Mean Sensitivity, Specificity, and Positive Pr
Previous TACE and Liver Segments Without Previous TACE
With Previous TACE
Without AEF With A
Sensitivity 31.9% (26.8%–37.3%) 48.4% (42.9%
Specificity 96.2% (94.1%–97.7%) 96.8% (94.7%
Positive predictive value 85.1% (77.5%–90.9%) 91.5% (86.4%
The 95% confidence interval is indicated in parenthesis.
AEF indicates arterial enhancement fraction; TACE,transarterial chemoembolizati
© 2015 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2015 Wolters Kluwer Hsetting of patients with advanced liver cirrhosis on the liver transplanta-
tion list.
On the basis of the presented data, we suggest a cutoff AEF value
of 50%, which is comparable with the results of Lee et al,21 who calcu-
lated a cutoff value of 45% in their analysis. We assume our result to be
more precise, since Lee et al used a per-lesion-based analysis, allowing
to count either true-positive or false-negative lesions, ignoring AEF
measurements in true-negative liver segments. This might be the reason
why our cutoff value is slightly higher.
With the use of the AEFmap, the performance of the radiologists
in detecting HCC lesions could be significantly improved, and
interreader variability was increased from moderate without the AEF
maps to substantial with addition of the AEF maps. In fact, the addi-
tional use of AEF maps could compensate the additive value of a fourth
CT contrast acquisition in equilibrium phase. This might allow super-
seding the fourth contrast acquisition in the equilibrium phase, which
would allow a dose reduction of 25%. This could be of interest to re-
duce cumulative radiation dose for patients with chronic liver disease
undergoing repetitive HCC screening with CT. There was a benefit ofedictive Value (Precision) of all Readers Between Liver Segments With
No Previous TACE
EF Without AEF with AEF
–53.9%) 42.3% (36.1%–48.8%) 51.6% (45.2%–57.9%)
–98.2%) 97.6% (96.8%–98.2%) 97.7% (96.9%–98.4%)
–95.2%) 69.5% (61.5%–76.8%) 75.0% (67.8%–81.3%)
on.
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FIGURE 4. Recurrent HCC after TACE. After TACE, there is a tumor necrosis in the center of the lesion (A, B, C; white asterisk), which can also be
seen in the corresponding histopathologic images (E; black asterisk). Recurrent nodular HCC on the medial and lateral border of the necrosis shows
arterial enhancement, but no clear washout in the portal venous phase. The lateral tumor border infiltrates the liver capsule (B, C; black arrows).
The arterial enhancement (AEF) map is positive, consistent with HCC activity (D; white arrows). On the corresponding hematoxylin and eosin–stained
histopathologic images, vital HCC cells (E; black arrow) and themicrospheres after TACE (E; white asterisk) are seen. A, unenhanced scan; B, arterial phase;
C, portal venous phase; D, arterial enhancement fraction (AEF) map; E, corresponding hematoxylin and eosin–stained histopathologic image.
Huber et al Investigative Radiology • Volume 51, Number 1, January 2016using the AEF nomatter if the lesion was located in liver segments with
or without previous TACE. However, there was an overall difference in
the detection of HCC lesions located in liver segments with previous
TACE compared with lesions located in segments without previous
TACE; lesions in segments with previous TACE were detected with
a lower sensitivity (31.89% without the AEF vs 48.36% with the
AEF) than HCC lesions located elsewhere (42.34%without the AEF vs
51.60% with the AEF). This can be explained by the reduced arterial
blood supply even if viable residual HCC tissue is present in this area,
once the arterial feeders have been embolized.22 The portal venous
blood supply, on the other hand, rests unchanged. This results in a re-
duction in arterial enhancement as well as a reduction in the washout
in the portal and the equilibrium phase. Inversely, HCC lesions located
in liver segments with previous TACE have been detected with a higher
PPV (85.12% without the AEF vs 91.53% with the AEF) than HCC
lesions located elsewhere (69.54% without the AEF vs 75.00% with
the AEF). This seems to be logical because a nodule in an area where
there was already an HCC is more likely to be an HCC than in an area
where there was no HCC.
In a setting of chronic liver disease, any lesion with arterial en-
hancement and washout on the grayscale images should be diagnosed
as HCC. Because these imaging characteristics are not always very well
identifiable, the AEF can help to raise confidence for HCC in cases of
weak arterial enhancement and/or uncertain washout. It is important to
note that the AEF is not a new imaging characteristic for HCC but a tool
that may help to better identify the known perfusion characteristics of
HCC. The AEF thus allows not only to detect lesions that have been
overlooked in the conventional readout but also to raise the sensitivity
by including HCC lesions with weak arterial enhancement and/or un-
certain washout without losing the high specificity of 96% to 98%. This
effect is reflected in a higher PPV when using the AEF maps. Or in30 www.investigativeradiology.com
Copyright © 2015 Wolters Kluwer Hother words, if lesions with weak arterial enhancement and uncertain
washout are called positive in an HCC screening setting to increase
the detection rate, the specificity will drop. The additional use of the
AEF helps to re-raise the specificity to the initial level. Two other major
signs to affirm the diagnosis of HCC beneath the perfusion charac-
teristics are the presence of a capsule and threshold growth between 2
imaging studies. The data published byYu et al5 investigating CT detec-
tion rate in liver transplant recipients showed a higher sensitivity of
65% for HCC-detection in fourphasic CT scans compared with this
present study, with a sensitivity of 42% for fourphasic acquisition with-
out AEF. There are different reasons that might explain this difference.
One reason is that Yu et al rated any liver lesion, even if it was not
clearly characterized as benign, as HCC. In the present study, only le-
sions with a confidence score of 3 of 5 given by the readers were called
positive. Another possible explanation for this difference is that Yu et al
excluded all HCC lesions with previous TACE. Last but not least, the
radiologists in the study of Yu et al were not blinded to other imaging
results, including ultrasound, CT, and MRI studies, and did have
knowledge of clinical information such as the serum alpha-fetoprotein
levels. The present study was designed to investigate the additional value
of the AEF, and the readers have thus been completely blinded to any
clinical information and were not allowed to look at previous or com-
plementary imaging studies. However, in a realistic setting of HCC
screening, the radiologists will always correlate the results to previous/
complementary imaging studies as well as clinical information and thus
might achieve better HCC detection rates than presented in this article.
Another study by Lee et al23 analyzing the additional use of AEF per-
fusion maps to detect HCC lesions with previous TACE also showed
a higher detection rate for the HCC lesions on fourphasic CT acquisi-
tion (sensitivity of 62.7%, compared with 42.1% in this study), as well
as on the fourphasic CTwith additional use of AEF maps (sensitivity© 2015 Wolters Kluwer Health, Inc. All rights reserved.
ealth, Inc. All rights reserved.
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ence between the 2 studies' methods is that Lee et al did not have a gross
pathologic explant as the gold standard to determine the true-positive
lesions because they did not investigate patients before liver transplan-
tation. Instead, they used the recommendations from the AASLD14 to
define positive HCC lesions. Many lesions that have been undetected
clinically and on CT scans thusmay not have been included, whichmight
explain the difference in performance compared with the present study.
The results of this study are confirmed by the paper of Peterson et al,24
who investigated triphasic CT detection rates before liver transplantation
compared with the histological analysis of the liver explants. Their re-
sults showed a sensitivity of 29% for the HCC lesions in the prospective
clinical reports, which is comparable with the sensitivity of 30.7% for
the triphasic CTacquisitions without the AEFmaps in the present study.
With or without the AEFmaps, the sensitivity for HCC detection
remained low in a population of patients with end-stage liver disease
on the liver transplantation list. Because HCC is often multifocal, the
per-patient sensitivity in a screening population will be higher than
the per-lesion sensitivity calculated in this study. Furthermore, small
HCC less than 2 cm will grow over time and might be detected in the
follow-up imaging study. Also, the radiologists should know the serum
alpha-fetoprotein level while reading the CT scans to achieve a better
screening performance, which was not the case in this study. In case
of an increased serum alpha-fetoprotein level and a negative CT scan,
perfusion MRI with gadoxetic acid and diffusion weighted imaging al-
lows to raise sensitivity for HCC detection up to 78.8% in a comparable
patient population with end-stage liver disease for an experienced radi-
ologist in the study of Hwang et al.25 However, bad clinical conditions
of patients on the liver transplantation list and presence of ascites in
these patients are major limitations for MRI studies.
The rather poor correlation between the serum alpha-fetoprotein
levels and the measured AEF values, as well as with the sum of the
HCC lesion diameter as measured by the hepatopathologist, can be ex-
plainedmainly by the heterogeneous tumor activity of HCC and the fact
that the alpha-fetoprotein level cannot be measured separately for each
HCC lesion. It is rather a marker for the total activity of the HCC mass
in 1 patient. Also, there are some limits in sensitivity and specificity of
the alpha-fetoprotein for HCC.26 However, there was a very good corre-
lation between the total HCC diameter in pathology and the total lesion
diameter with an AEF greater than 50%. A further study comparing the
sum of AEF values per tumor volume with the serum tumor markers in
a larger series of patients would be very promising.
Hepatocellular carcinoma screening is recommended by most
societies for chronic liver disease, whereas normally a screening inter-
val of 6 months with ultrasound and biomarkers is advised.27 However,
knowing the low detection rates for small HCC lesions with ultrasound
in a patient population with end-stage liver disease, CT or MRI is rec-
ommended by the AASLD in patients with a hepatic nodule bigger
than 1 cm.14 Also, it might be used in obese patients who are difficult
to examine with ultrasound,28 as well as in patients with previous, treated
HCC.29 There is a new recommendation for liver imaging reporting and
data system (Liver ImagingReporting andData System) by the American
College of Radiology to standardize the reporting and data collection
of CT and MRI for HCC in these patients.30 Beyond the arterial phase
hyperenhancement and the washout phenomenon, it also takes into ac-
count a threshold growth of the lesion and the presence or absence of a
capsule around the lesion.31
Limitations
A major weakness of this study is its retrospective nature and
the homogenous patient population with end-stage liver cirrhosis on
the OLT list. In a patient population with less advanced chronic liver
disease, the detection rate for HCC would probably be higher because
patients with end-stage liver disease will show a more heterogeneous© 2015 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2015 Wolters Kluwer Hliver enhancement with the presence of more regenerative nodules.
Thus, the resulting calculated AEF maps are also likely to be more
heterogeneous than the AEF maps of patients with less advanced
chronic liver disease. Another factor is the reduced general condition
with difficult image acquisition in the present patient population due
to motion artifacts and ascites. Although the parenchyma of the cir-
rhotic livers is very stiff, there will always be some deformation of
the liver parenchyma in the presence of respiration between the dif-
ferent CT acquisitions. The different acquisitions will never match
perfectly to calculate AEF maps, even in case of an optimal motion
correction.
Another weakness of the study is that the readers were grouped
into 1 group looking at 3 contrast phases (unenhanced, arterial, and por-
tal venous phase) and 1 group looking at 4 contrast phases (unenhanced,
arterial, portal venous, and equilibrium phase) during the conventional
readout. This was done to allow a comparison of 3 versus 4 contrast
phases but diminishes the statistical power of the study. Nevertheless,
the results have been significant; the detection rate of the triphasic CT
acquisitions without the AEF of group 1 were compatible with the re-
sults of Peterson et al, who also analyzed detection rates of HCC lesions
in triphasic CT scans of liver transplant recipients with direct pathologic
correlation to the liver explants. There was no significant difference
in performance between the 2 reader groups comparing the 2 readouts
using the AEF perfusion maps. The κ statistic showed a substantial
mean unweighted interreader variability between the 6 readers for the
triphasic readout with the AEF tool.
The fact that the readerswere completely blinded to complementary/
previous imaging studies and clinical information was intended for
the objectives of this study, but radiologists will always consider clini-
cal information and compare it with previous imaging studies in a real
setting of HCC screening. This could lead to a better HCC detection
rate than shown in this study. A possible use of the AEF maps in com-
bination with 4 contrast acquisitions has not yet been analyzed. This
could be of interest to additionally increase detection rates and should
be done in a further, optimally prospective study.CONCLUSION
This radiologic-pathologic correlation study shows that AEF is
a helpful tool to screen for HCC in patients on the OLT list. We recom-
mend a cutoff value of 50% for the AEF. The use of AEF maps may
significantly improve sensitivity and precision (PPV) of HCC detec-
tion and a decrease interreader variability.
There was no significant difference in performance of a triphasic
CTusing AEF compared with a fourphasic CTwithout AEF. This might
allow a 25% reduction in radiation dose, which is relevant for patients
undergoing repetitive HCC screening with CT.
Lesions located in liver segmentswith previous TACE have been
detected with a lower sensitivity than lesions located in liver segments
without previous TACE. On the contrary and not surprisingly, the
PPV was better in liver segments with previous TACE. In both scenar-
ios, a beneficial use of the AEF perfusion maps has been shown.REFERENCES
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